Navigation Links
Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinson's Disease Target LRRK2
Date:12/16/2010

LA JOLLA, Calif., Dec. 16, 2010 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S (Lundbeck) utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2.  Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

"We are pleased that our expertise in protein expression, purification and crystallization has been recognized by a leader in CNS drug discovery and look forward to a long and productive relationship with Lundbeck," says Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.

"Zenobia has a strong structural biology team and the lead on this important Parkinson's target.  We are pleased to be working with them," says Klaus Baek Simonsen, Head of Discovery Chemistry at H. Lundbeck A/S.

Under the agreement, Zenobia will complete x-ray crystal structures of wild-type and the Parkinson's disease-associated mutant, G2019S, in complex with Lundbeck lead compounds.  Zenobia retains all rights and ownership of the LRRK2 structure and to their internal LRRK2 chemistry program.

About Zenobia

Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there is no disease altering treatment such as Parkinson's disease and pediatric neuroblastoma.

www.zenobiatherapeutics.com

About Lundbeck

H. Lundbeck A/S (LUN.CO,
'/>"/>

SOURCE Zenobia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
2. Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2010 Financial Results on October 28
3. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
4. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
7. ActiveCare, Inc. Announces Strategic Relationship With Vista Therapeutics, Inc. in Developing Nano Biosensors for the Elderly
8. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
9. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
10. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
11. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... Washington, USA (PRWEB) September 16, 2014 ... to create the features that we desire in optical ... Center at Montana State University. “As we explore surfaces ... Some of those lessons were presented in San Diego ... of Light: Light in Nature ” chaired by Shaw ...
(Date:9/16/2014)... 16, 2014 --The emerging field of molecular electronics ... next level, enabling the construction of tiny circuits ... individual molecules would take on the roles currently ... A team of researchers from five Japanese and ... use in small-scale electronics: a molecule called picene. ...
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... DIEGO, April 15 Mr. Glynn has over 34 ... is well,known within the life sciences industry for his ... Most notably, Mr. Glynn,retired from Invitrogen Corporation (Nasdaq: ... company, he held several operating roles including CFO,President and ...
... NEW HAVEN, Conn., April 15 Vion,Pharmaceuticals, Inc. (Nasdaq: ... a,plan to achieve and sustain compliance with The Nasdaq ... of the plan., Previously, the Company announced that ... The Nasdaq Stock Market, Inc., notifying the Company,that it ...
... April 15 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... the,American Association for Cancer Research (AACR) in San Diego. ... of the HGF,receptor tyrosine kinase (MET), inhibits growth of ... the afternoon poster session,entitled Small Molecule Kinase Inhibitors 1 ...
Cached Biology Technology:eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2Vion Pharmaceuticals Files Plan With Nasdaq 2Vion Pharmaceuticals Files Plan With Nasdaq 3SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3
(Date:9/17/2014)... Trees have been growing significantly faster since the 1960s. ... barely changed, but they have accelerated -- by as ... a study carried out by scientists from Technische Universitt ... that have been continuously observed since 1870. Their findings ... Three decades ago, "forest dieback" was a hot topic, ...
(Date:9/16/2014)... women in Australia is increased by lower socioeconomic ... September) in BJOG: An International Journal of ... high standards of living; however, existing research has ... indigenous and non indigenous Australians. , This case-control ... socioeconomic position on severe maternal morbidities associated with ...
(Date:9/16/2014)... taught us that we inherit certain traits from our ... change how these genes play out by taking certain ... That,s exactly what a team of researchers at the ... their research of epigenetics research. , Epigenetics regulates ... DNA and histone proteins, which prevent permanent mutations or ...
Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... MCLEAN, Va., Nov. 29, 2012  Northrop Grumman Corporation (NYSE: ... proof of concept for an automated biometric information system ... will be operated for a trial period to enable ... enabled intelligence and to help determine the requirements for ...
... William Cooke, a professor in the UTSA College of Education ... selected to serve as the speaker of the Texas Chapter ... Tour. Over the course of a week, Cooke will deliver ... of ACSM,s Texas Chapter. "This is a big honor ...
... For the first time in its history, the American Society ... opening session of the ASCB,s Annual Meeting, for "An Evening ... Francisco, on Saturday, Dec. 15. Members of the ... will receive complimentary registration to the ASCB keynote addresses ...
Cached Biology News:Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2UTSA physiologist William Cooke named 2013 Lecture Series Speaker by Texas Sports Medicine Chapter 2Public invited to 'An Evening of Science & Art' at ASCB Annual Meeting 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: